CAR-T Archives

November 18, 2022

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

Very complex, promising research is currently underway to use humanized bispecific single-domain antibodies (bsVHH). But, unfortunately, harnessing the immune system can get very complicated. This article introduces an experimental antibody with a novel approach to fighting CLL/SLL.

November 14, 2022

Depletion of CLL Cells by Venetoclax Treatment Reverses Oxidative Stress and Impaired Glycolysis in CD4 T cells

Our immune system is a complex organization of lymphocytes, myeloid cells (granulocytes, macrophages, dendritic cells), complement factors, cytokines, and other chemical mediators, which all work together to fend off disease and infection.

September 13, 2022

ASH 2021: Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Dr. Mazyar Shadman and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).

August 26, 2022

ASH 2021: Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

These results are encouraging and show that patients with relapsed/refractory B-cell NHL treated with bispecific LV20.19 CAR T-cells have a high overall response rate and low rates of grade ≥3 CRS or ICANS.

June 30, 2022

ASH 2021: Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

In this study presented at the American Society of Hematology Annual Meeting and Exhibition (ASH 2021), the authors evaluated the effectiveness of triple gene-modified cells, called “iDuo” Natural Killer (NK) cells. Dr. Alex Danilov interviews Dr. Veronika Bachanova, MD, Professor of Medicine and Director of Cell Therapies and Hematologic

February 9, 2022

Can CAR T-Cell Therapy Truly Cure CLL/SLL?

The short answer is that it is certainly beginning to look that way for a lucky few. This month celebrated the 10th CAR-T anniversary of Doug Olson, who remains cancer-free with persistent CAR-T cells that still play WHACK-A-MOLE should any cancerous CLL cells dare to reappear.

February 6, 2022

CLL Society Education On Demand: ASH 2021 Comes to You

CLL Society brings ASH 2021 to you! The American Society of Hematology Annual Meeting had important research presented and now Drs. Anthony Mato and Brian Koffman will highlight findings that you should know when considering future treatment options.

December 23, 2021

CAR-T Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Made Easy to Understand

CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL/SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You can learn more about CAR-T therapy in this easy-to-understand CAR-T brochure that can be viewed in this digital flipbook format

September 14, 2021

Did You Know Q3 2021

Learn some key facts and data points about CLL and CAR-T therapy.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

CAR-T

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

Depletion of CLL Cells by Venetoclax Treatment Reverses Oxidative Stress and Impaired Glycolysis in CD4 T cells

ASH 2021: Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

ASH 2021: Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

ASH 2021: Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

Can CAR T-Cell Therapy Truly Cure CLL/SLL?

CLL Society Education On Demand: ASH 2021 Comes to You

CAR-T Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Made Easy to Understand

Did You Know Q3 2021

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT